Streptococcus pyogenes Infections - Pipeline Review, H2 2017

  • ID: 4333999
  • Report
  • 37 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Absynth Biologics Ltd
  • Antibiotx ApS
  • AstraZeneca Plc
  • Crestone Inc
  • Emergent BioSolutions Inc
  • Griffith University
  • MORE
Streptococcus pyogenes Infections - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Streptococcus pyogenes Infections - Pipeline Review, H2 2017, provides an overview of the Streptococcus pyogenes Infections (Infectious Disease) pipeline landscape.

Streptococcus pyogenes infections are caused by Streptococcus pyogenes, a spherical, Gram-positive bacterium. Symptoms include significant pain, swelling, and redness of infected area, fever, dizziness, difficulty breathing, dangerously low blood pressure, and a weak, rapid pulse. Treatment includes antibiotics and healthy lifestyle.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Streptococcus pyogenes Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Streptococcus pyogenes Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Streptococcus pyogenes Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Streptococcus pyogenes Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 4 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Streptococcus pyogenes Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Streptococcus pyogenes Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Streptococcus pyogenes Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Streptococcus pyogenes Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Streptococcus pyogenes Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcus pyogenes Infections (Infectious Disease)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Streptococcus pyogenes Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Streptococcus pyogenes Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Absynth Biologics Ltd
  • Antibiotx ApS
  • AstraZeneca Plc
  • Crestone Inc
  • Emergent BioSolutions Inc
  • Griffith University
  • MORE
Introduction

Streptococcus pyogenes Infections - Overview

Streptococcus pyogenes Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Streptococcus pyogenes Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Streptococcus pyogenes Infections - Companies Involved in Therapeutics Development

Absynth Biologics Ltd

Antibiotx ApS

AstraZeneca Plc

Crestone Inc

Emergent BioSolutions Inc

Griffith University

Helix BioMedix Inc

Wellstat Vaccines LLC

Streptococcus pyogenes Infections - Drug Profiles

AZ-6142 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EV-035 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-1345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

niclosamide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus [serotype A] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes (30-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Streptococcus pyogenes Infections - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Streptococcus pyogenes Infections, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Streptococcus pyogenes Infections - Pipeline by Absynth Biologics Ltd, H2

Streptococcus pyogenes Infections - Pipeline by Antibiotx ApS, H2

Streptococcus pyogenes Infections - Pipeline by AstraZeneca Plc, H2

Streptococcus pyogenes Infections - Pipeline by Crestone Inc, H2

Streptococcus pyogenes Infections - Pipeline by Emergent BioSolutions Inc, H2

Streptococcus pyogenes Infections - Pipeline by Griffith University, H2

Streptococcus pyogenes Infections - Pipeline by Helix BioMedix Inc, H2

Streptococcus pyogenes Infections - Pipeline by Wellstat Vaccines LLC, H2

Streptococcus pyogenes Infections - Dormant Projects, H2

List of Figures

Number of Products under Development for Streptococcus pyogenes Infections, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Absynth Biologics Ltd
  • Antibiotx ApS
  • AstraZeneca Plc
  • Crestone Inc
  • Emergent BioSolutions Inc
  • Griffith University
  • Helix BioMedix Inc
  • Wellstat Vaccines LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll